Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

PRESCRIBER	PATIENT:
Name:	Name:
Ward:	NHI:
Palivizumab	
support (see Note A) in the community Child has haemodynamically signific and Child has unoperated simple compositions and Child has unoperated or surgice or Child has severe pulmonary hyor Child has moderate or severe or Child has severe combined immune deficient transplant	al or neuromuscular disease that requires ongoing ventilatory/respiratory cant heart disease congenital heart disease with significant left to right shunt (see Note cally palliated complex congenital heart disease

l confirm	that	the	above	details	are	correct:
-----------	------	-----	-------	---------	-----	----------

	?:l.	D-1	
- 3	Ziuneu.	Date:	
•	Jigi ica.	 Duic.	

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

PRESCRIBER	PATIENT:
Name:	Name:
Ward:	NHI:
Palivizumab - continued	
or Note A) in the community Child has haemodynamically significant heart dia	uscular disease that requires ongoing ventilatory/respiratory support (see sease eart disease with significant left to right shunt (see Note B) d complex congenital heart disease (see Note C)
or	ned by an immunologist, but has not received a stem cell transplant ncrease susceptibility to life-threatening viral respiratory infections,

Note:

- a) Ventilatory/respiratory support includes those on home oxygen, CPAP/VPAP and those with tracheostomies in situ managed at home
- b) Child requires/will require heart failure medication, and/or child has significant pulmonary hypertension, and/or infant will require surgical palliation/definitive repair within the next 3 months
- c) Mean pulmonary artery pressure more than 25 mmHg
- d) LV Ejection Fraction less than 40%
- e) Inborn errors of immunity include, but are not limited to, IFNAR deficiencies

I confirm that the above details are correct:		
Signed:	Date:	